Stammzellen - 500 Beiträge pro Seite

[toller]

was ist heute mit Aastrom, Stemcells, Cord Blood und anderen los? teilweise >10% nach wochenlangem "dahingeplätscher"? Weiß jemand etwas?

[Sugar2000]

denke es liegt an den Demokraten in den USA... die wollen ja die Stammzellenforschung enorm fördern... Bush kann jedoch "noch" Veto einlegen...

[schnutzelpuh]

Der Bush hat doch fertig. Der muss sich bei den Demokraten jetzt ein wenig einschleimen, um einen geordneten Rückzug hinzubekommen. Das wird aber auch nichts daran ändern, dass er als schlechtester Präsdient aller Zeiten in die Geschichte der USA eingehen wird. Und die Merkel die dumme Nuß, kriecht dem noch in den Hintern.

[toller]

nur zur info: stimmt, das mit den Demokraten (posting #2)
poste nachher noch eine Begründung warum ausgerechnet Cord Blood america am Freitag nochmal 69% in USA gestiegen ist.

Biotech Shares Rise on Stem Cell Bill
Thursday January 4, 6:13 pm ET
By Matthew Perrone, AP Business Writer
U.S. Stem Cell Developers Get Boost As Democrats Look to Increase Federal Funding

WASHINGTON (AP) -- Shares of biotech companies working on stem cell-related therapies surged Thursday as Democrats in Congress prepared to promote once again legislation that would increase government-funded research in this area.

ADVERTISEMENT
House Democrats are expected to propose a bill on Friday that will expand the types of stem cell research that can be funded by the government. In 2001 President George W. Bush said his administration would only allow funding for research using a limited number of stem cell types, and last summer he vetoed a bill passed by Congress that would have eased those limits. It was the first and only veto of his presidency.

With a new majority in Congress -- and support from many Republicans -- House Democrats have promised to push the legislation through in their first 100 hours in power. A House vote is scheduled for next Thursday.

If Bush rejects the bill again, the 100-member Senate is believed to have enough support to overturn his veto with a two-thirds majority vote, though the 435-member House would have a more difficult time getting the necessary votes.

Even if the current legislation does not get through, stem cell research advocates say lawmakers could get it passed down the road by attaching it to a critical bill that the president would have to sign.

"We're hopeful that the president learned something from the election results, but if he didn't and chooses to veto this bill again, that doesn't mean the game is up," said Sean Tipton, President of the Coalition for the Advancement of Medical Research.

Many states previously decided not to wait for federal money to fund stem cell research. California's Institute for Regenerative Medicine is expected to deliver $181 million this year to scientists working on stem cell-related cures in that state. New Jersey, Connecticut, and Maryland are among the other states that have designated funding for stem cell researchers.

With the possibility of increased funding on the horizon, traders sent the price of Stemcells Inc. stock up more than 15 percent. Shares dipped 2 cents in after hours trading Thursday after rising 45 cents, or 16.9 percent, to close at $3.11 on the Nasdaq Stock Market.

In November the company helped perform the first ever transplant of cells from an aborted fetus into a living patient as part of an experimental treatment for Batten's disease, a neurological disorder.

Shares of tissue repair developer Aastrom Biosciences rose 1 cent in after hours trading after rising 15 cents, or 12 percent, to close at $1.39 on Nasdaq. The Ann Arbor, Mich.-based company is aiming to use stem cells to regrow bone and regenerate tissue.

Shares of Alameda, Calif.-based Advanced Cell Technology also rose more than 14 percent on the possibility that federal funding could soon flow to the stem cell therapy innovator.

Shares rose 13 cents, or 23.6 percent, to close at 68 cents on the over-the-counter market.

Last summer Advanced Cell Technology Inc. came to national attention after it revealed a technique to grow stem cells from a single human cell taken from a human embryo. Prior methods for harvesting stem cells require the destruction of human embryos, which many Americans, including Bush, see as unethical.

Fellow California biotech company Cord Blood America saw its shares rise 2.9 cents, or 30 percent, to close at 12 cents on the over-the-counter market. The company collects and preserves umbilical cord blood from newborn infants for use in future stem cell treatment. Cord Blood issued a release Thursday stating that blood collected by the company was used for the first time in the treatment of childhood leukemia by doctors at the University of Pennsylvania.

[toller]

übrigens interessant: zu corecell gehört die deutsche company namens Vita34 (von deren hoempage "2004:
Merger mit CorCell Inc. USA.), hab da aber nicht weiter nachgeforsct.

hier die Meldung zur erfolgreichen Transplantation von Stammzellen aus Nabelschnur bei einer 3Jährigen, an Leukämie erkrankten Patientin. Heute, im ALter von 6 Jahren scheint das Mädchen geheilt. Weiter unten folgt auch noch ne deutsche Meldung von Vita 34.

CorCell, a Cord Blood America Company, Announces First Autologous Cord Blood Transplant for Childhood Leukemia Worldwide
Thursday January 4, 5:00 am ET

LOS ANGELES and PHILADELPHIA, Jan. 4 /PRNewswire-FirstCall/ -- CorCell (http://www.corcell.com), a Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News) company (http://www.cordblood-america.com), today announced that cord blood collected and stored by one of its private, family customers was used in what is believed to be the first autologous cord blood transplant for childhood leukemia anywhere in the world. Autologous cord blood is that collected from a baby's umbilical cord and for use specifically for that child.

ADVERTISEMENT
click here
"This is the first time we have evidence that umbilical cord blood (UCB) can be used in an autologous transplant to treat childhood leukemia," states Jack Goldberg, MD, CorCell Medical Director and Chief of Hematology Oncology at the University of Pennsylvania Health System, PennPresbyterian. "This is critical because it removes the misconception existing in the medical profession that the collection of cord blood for autologous transplantation in the treatment of childhood leukemia was not possible. Importantly, we now know this is not the case."

The Official Journal of the American Academy of Pediatrics released the report, "First Report of Autologous Cord Blood Transplantation in the Treatment of a Child with Leukemia," in Pediatrics 2007; 119: 296-300 on January 3, 2007.

In this first known worldwide reported case, a 3-year-old girl with leukemia was transplanted with her own stored umbilical cord blood after developing isolated central nervous system relapse. This occurred 10-months after diagnosis while she was receiving chemotherapy. More than two years after transplantation with her own cord blood she is still free of leukemia at age 6. Molecular testing was performed on the cord blood for the detection of the leukemia clone. It was not found, showing that the leukemia was not present at birth. Initially, a search was undertaken for a match within the family and could not be found. The treating physician stated in the report that, "The decision made by the parents of our patient to save the UCB may have increased the patient's chances of survival." The authors of the report said that the acute lymphoblastic leukemia the three-year-old child presented with is the most common malignancy in children.

"Since CorCell's inception in 1995 as a private, family cord blood bank we have supported both private and public cord blood banking," said Marcia A. Laleman, CorCell's President. "We believe there is a place for both. As medical treatment and research continue to expand the use of cord blood, families should have the option of storing privately or donating to a public bank. The probability that a child's cord blood stem cells will be needed is about 1:2000 during childhood and increases through age 70 to 1:7."

"It is an outstanding day for the cord blood industry and the families who bank their baby's cord blood when yet another treatment opportunity is developed for umbilical cord blood stem cell transplantation," says Matthew Schissler, CEO of Cord Blood America. "With more than 60 clinical trials underway in the United States involving UCB, research is forging ahead to find additional uses for cord blood stem cells. This is an industry that saves lives and of which Cord Blood America and CorCell are tremendously proud to be a part."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, www.corcell.com, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc.'s private cord blood bank, CorCell, visit our website at www.corcell.com. For Cord Blood America (OTC Bulletin Board: CBAI - News) investor information, visit www.cordblood-america.com.



Meldung von Vita Cell:
Weltweit erstmals eigenes Nabelschnurblut zur Behandlung von Leukämie eingesetzt
Leipzig, 4.1.2007: Zum ersten Mal weltweit ist ein Kind mit einer Leukämie erfolgreich mit dem eigenen Nabelschnurblut behandelt worden. Das berichten deutsche und amerikanische Ärzte in der Januar-Ausgabe der Fachzeitschrift „Pediatrics“. Das Nabelschnurblut war bei der US-Tochter der deutschen Nabelschnurblutbank Vita 34 aufbereitet und gelagert worden. 24 Monate nach der Behandlung ist das heute sechsjährige Mädchen frei von Leukämiezellen.

Das Mädchen war im Alter von drei Jahren an einer akuten lymphoblastischen Leukämie erkrankt. Der erste Behandlungsversuch mittels Chemotherapie war fehlgeschlagen. Deswegen erfolgte vier Monate später am Advocate Hope Children’s Hospital in Oak Lawn (Illinois, USA) eine zweite Chemotherapie mit anschließender Infusion von Nabelschnurblut. Das stammzellreiche Nabelschnurblut war von den Eltern bei der Geburt des Kindes als Vorsorge bei Corcell, der US-Tochter der Leipziger Nabelschnurblutbank Vita 34, aufbewahrt worden. „Wir haben bewiesen, dass die Infusion von Stammzellen aus dem eigenen Nabelschnurblut auch bei Leukämie eine sichere und Erfolg versprechende Behandlungsmöglichkeit sein kann“, sagt Dr. med. Eberhard Lampeter, Gründer und Vorstand der Vita 34 AG.

Nabelschnurblut enthält außergewöhnlich viele und vor allem junge Stammzellen.
Wenn sie zur Geburt entnommen und aufbewahrt werden, stehen sie einem Menschen ein Leben lang für den Erkrankungsfall zur Verfügung. „Die Wahrscheinlichkeit, die Stammzellen zu benötigen, nimmt mit dem Alter eines Menschen zu“, so Lampeter. „Bei Kindern beträgt sie etwa 1:2000, bis zum Alter von 70 Jahren steigt das Risiko auf 1:7.“

Vita 34 ist die führende Nabelschnurblutbank in Europa und wurde 1997 von Ärzten in Leipzig gegründet. In Deutschland haben sich bislang über 38.000 Eltern entschieden, das Nabelschnurblut ihres Kindes als „biologische Lebensversicherung“ bei Vita 34 aufzubewahren. Stammzellpräparate von Vita 34 wurden bereits mehrfach zur Behandlung von Patienten sowie im Rahmen der medizinischen Forschung zur Herzinfarkt- oder Schlaganfalltherapie eingesetzt.

Originalartikel:
Hayani A, Lampeter E, Viswanatha D, Morgan D, Salvi SN: First Report of Autologous Cord Blood Transplantation in the Treatment of a Child With Leukemia. Pediatrics 2007; 119: e296-e300.

[toller]

so, letztes posting zu dem thema heute (zwei Artikel):
warum steigen z.b. astm und stem heute weiter? Es gab eine meldung, demnach es forschern gelungen ist, Stammzellen aus Fruchtwasser zu
"gewinnen".


US-Forscher entdecken Fruchtwasser als neue Quelle für Stammzellen
Die Wissenschaftler sehen in den Zellen großes Potenzial: Sie stammten nachweislich vom Kind, ließen sich leicht gewinnen und tiefgekühlt in Zellbanken aufbewahren. Die neuen Erkenntnisse könnten die ethisch umstrittene Stammzellenforschung deutlich erleichtern.

Washington - US-Wissenschaftler haben offenbar eine weitere Möglichkeit der Stammzellengewinnung entdeckt: Die wandelbaren Zellen seien nicht nur in Embryonen und im Menschen, sondern auch im Fruchtwasser zu finden und ließen sich auch zum späteren Gebrauch für das neue geborene Kind aufbewahren, berichteten Forscher des Instituts für regenerative Medizin an der Wake Forest University School of Medicine auf der Internetseite des Fachmagazins „Nature Biotechnology“.

Die Wissenschaftler entwickelten eigenen Angaben zufolge aus den Zellen bereits Muskel-, Knochen-, Fett, Blutgefäß-, Nerven- und Leberzellen. Die jüngsten Ergebnisse könnten die bislang wegen der Zellgewinnung höchst umstrittene Stammzellenforschung deutlich erleichtern. Stammzellen gelten als Hoffnungsträger bei der Behandlung von zahlreichen Krankheiten wie Krebs, Alzheimer und Parkinson, da sie anders als andere Zellen im Körper nicht auf ihre Funktion festgelegt sind und sich in alle möglichen Zelltypen entwickeln können.


Die leistungsfähigsten Stammzellen wurden bislang aus wenigen Tagen alten Embryonen gewonnen, die bei der Entnahme jedoch zerstört wurden. Stammzellen im Körper des Menschen sind weniger variabel einsetzbar. Auch in der Nabelschnur befindet sich ein bestimmter Typ von Stammzellen - diese Zellen kommen vorwiegend bei der Behandlung von Leukämie zum Einsatz.

Fast so leistungsfähig wie embryonale Stammzellen

Die Stammzellen aus dem Fruchtwasser seien fast so leistungsfähig wie embryonale Stammzellen, sagte der Leiter der Studie Anthony Atala. „Wir hoffen, dass diese Zellen eine wertvolle Ressource für die Gewebezüchtung und auch für gezüchtete Organe sein werden.“ Bei Versuchsreihen an Mäusen seien die neu entdeckten Stammzellen bereits verwendet worden, um beschädigte Gehirnzellen zu ersetzen.

Die Zellen tragen das genetische Material des Embryos. Eine Stammzellenbank mit 100.000 verschiedenen Fruchtwasser-Stammzellen könnte nach Angaben von Atala 99 Prozent der US-Bevölkerung mit passenden genetischem Material für Transplantationen versorgen. Trotz der jüngsten Erkenntnisse werde es aber noch einige Jahre dauern, bis die Methode am Patient zum Einsatz käme. „Wir stehen mit der Arbeit noch am Anfang“, sagte Atala.

In Deutschland unterliegt die Stammzellenforschung strengen Auflagen. Die Forschung an embryonalen Stammzellen ist weitgehend verboten. Das deutsche Embryonenschutzgesetz verbietet jede Verwendung von Embryos, die nicht einer Schwangerschaft dient. Nach dem Stammzellengesetz darf auch an importierten Zellen nur geforscht werden, wenn sie vor 2002 angelegt wurden.




Stem Cell Stocks Rise

By Althea Chang
TheStreet.com Staff Reporter
1/8/2007 3:50 PM EST
Click here for more stories by Althea Chang


Stem cell stocks rose Monday after researchers said they found stem cells in the amniotic fluid that cushions fetuses in pregnant women.

The news sent some highly speculative stem cell stocks higher. Some investors were betting the finding shows how scientists can steer clear of controversy over the destruction of embryos in medical research.

Among stem cell stocks moving higher Monday were Osiris Therapeutics (OSIR - commentary - Cramer's Take), gaining 4.9% to $25.56; Aastrom Biosciences (ASTM - commentary - Cramer's Take - Rating), up 8.3% to $1.57; ViaCell (VIAC - commentary - Cramer's Take - Rating), rising 9.7% to $5.56; and StemCells (STEM - commentary - Cramer's Take - Rating), 5.4% higher to $3.50.

"The amniotic stem cell findings are promising, but it's still early stage," says Jose Haresco, analyst at investment research firm Merriman Curhan Ford.

According to research published in a recent issue of the journal Nature Biotechnology, amniotic fluid contains a number of different cell types that can develop in the same way embryonic cells can. Researchers prize stem cells for their ability to develop into the building blocks of all kinds of tissue -- a trait that they believe could lend itself to fighting disease.

Amniotic fluid is extracted from the protective sac that surrounds the fetus, not from the fetus itself. The Bush administration has restricted federal funding for embryonic stem cell work since 2001.

"Democrats taking back at least part of the government has created a positive trading environment for these stocks," Haresco says, referring to Democratic gains in Congress in the most recent elections. But the research is preliminary. Researchers have yet to prove that stem cells can effectively and reliably treat diseases and wounds in humans.

"Institutional investors want something to hang their hat on," Haresco says. "Retail investors trade the stocks off of what happens in the news."

[toller]

Friday, January 12, 2007
Stem Cell Stocks Drop As Congress Fails to Muster Enough Votes

by H.S. Ayoub
BioHealth Investor.com



The new congressional vote to allow increased federal funding for embryonic stem cell research failed to garner the required two-thirds necessary to over-ride an expected veto by President Bush.

The House of Representatives passed the bill to allow expanded federal funding for the research with a 253 to 174 vote, 6% shy of the required 66%.

This is a major setback for the burgeoning field as president Bush's current limitations on the research, imposed back in 2001, has forced many top stem cell experts to leave the United States for Europe and Asia.

This will surely force member states to adopt their own funding policies. Already, California and New Jersey have allocated millions of dollars for embryonic stem cell research.

The private sector continues to fund the research as well, but without the deep pockets of government institutions, such as the National Insitutes of Health (NIH), embryonic stem cell research will not expand fast enough, nor will the U.S. attract top researchers in the field.

Stem cell stocks were down on Friday. StemCells (STEM) dropped 9%, Aastrom (ASTM) lost 6%, while Geron (GERN) and ViaCell (VIAC) both sank about 3% on the day.

[toller]

Aastrom Biosciences
ASTM, Price: $1.41 (1/17/07); Market Cap: $168.9 MM (1/17/2007) Market Outperform Rating; Target Price: $2
Rodman&Renshaw Ren Benjamin, PhD – Senior Biotechnology Analyst (212.430.1743)

[toller]

Aastrom Gets FDA Orphan Drug Status
Thursday February 1, 2:42 pm ET
Aastrom Biosciences Receives FDA Orphan Drug Designation for Enlarged Heart Disease Treatment

ANN ARBOR, Mich. (AP) -- Aastrom Biosciences Inc., a biotech company that develops cells that repair human tissue, said Thursday it received an orphan drug designation from the Food and Drug Administration to treat a type of heart disease.

Orphan drug status is granted to treatments for diseases that affect less than 200,000 people in the U.S. The designation gives the treatment seven years of marketing exclusivity if approved, and allows for tax breaks and developmental assistance.

Aastrom received the designation for its Tissue Repair Cells to treat dilated cardiomyopathy, a disease where the heart gets larger and the ability to pump blood drops to the point where normal blood circulation cannot be maintained.

Shares of Aastrom rose 6 cents, or 4.5 percent, to $1.38 in afternoon trading on the Nasdaq.

[toller]

Aastrom Biosciences Posts Wider 2Q Loss
Wednesday February 7, 9:24 am ET
Aastrom Biosciences 2nd-Quarter Net Losses Widen Slightly on Higher Research Costs

ANN ARBOR, Mich. (AP) -- Aastrom Biosciences Inc., which develops technology to repair tissue cells, on Wednesday posted a modestly wider fiscal second-quarter loss as research and development costs jumped.

The stem cell research company, whose products are still in clinical trial stages, said losses grew to $4.2 million from $4.1 million. Per-share loss was flat at 4 cents, as the company reduced the number of shares outstanding by 14 percent.

Quarterly revenue, made up of limited therapy kit sales for research by others and grants, rose to $158,000 from $117,000.

Costs increased to $4.9 million from $4.5 million year over year, including a 17 percent jump in research and development expenses to $2.6 million.

Analysts surveyed by Thomson Financial expected a loss of 4 cents per share, on par with results, on $160,000 in revenue.

The company's stock dipped 2 cents in premarket activity to $1.38 per share.

[diegutefee]

Hallo Freunde,

schaut mal bei "Stem Cell Innovations" vorbei!

Kürzel: scll (in USA)

Herzliche Grüße

diegutefee

[toller]

Aastrom lief in letzter zeit nicht so toll, zeigt mal wieder deutlich, wie unreif dieser Stammzellenmarkt noch ist, allerdings steckt meiner meinung nach viel Phantasie in den Stemcell Werten. Die hohe volatilität tut ihr übriges. Wie schnell sich das Blatt wenden kann zeigt Biostem, die noch Anfang November bei 3,55$ lagen, dann auf knapp 0,55 gefallen sind bis letzte Woche und dann nur nach erfolgreicher Finanzierungsrunde innerhalb von 4 Tagen auf 2,2$ hochschossen. Momentan wieder bei 1,5$.

hier ein Artikeln zu Stammzellen Aktien:

Capital markets remain chilly for stem cell companies
By Carolyn Pritchard, MarketWatch
Last Update: 5:09 PM ET Mar 14, 2007

SAN FRANCISCO (MarketWatch) -- Though market downturns such as the current one usually leave no industry untouched, their effect can be most pronounced -- and lasting -- in nascent, early-stage niche industries such as stem cells.
"It's the general malaise: when the capital markets catch a cold, the biotech markets catch pneumonia," said analyst Stephen Brozak of WBB Securities. "We are now looking at a problematic capital market in biotech and a doubly problematic market for stem cell companies."
The Dow Jones Industrial Average fell more than 100 points to below 12,000 for the first time since late 2006 midday Wednesday, before recovering to close higher. See Market Snapshot.
Embryonic stem cells are derived from embryos that develop from eggs that have been fertilized in vitro, not in a woman's body. Adult stem cells, conversely, are found in a tissue or organ.
Supporters of stem cell research believe it will eventually provide treatments and even cures for some of the most devastating afflictions, such as spinal cord injury, Parkinson's disease, Alzheimer's disease, stroke, Lou Gehrig's disease and juvenile diabetes.
Opponents of embryonic stem cell research contend that because culling stem cells results in destruction of embryos, the research destroys human life.
Stem cell companies have always been near the back of the funding line, especially after President Bush in 2001 limited federal funding to embryonic stem-cell lines already in existence at the time. Then in 2004, the California Stem Cell Research and Cures Act, or Prop. 71, was approved by voters, creating a state-controlled agency to oversee the issuance of $3 billion in bonds. Those bonds translate into about $300 million a year in grants over 10 years for stem cell research at California universities and research institutions.
Though public companies won't be the main recipients of such funds, and the bonds remain tied up in court, Prop. 71's very existence rekindled investor interest in stem cells.
"Just the education of the value, of these valuable stem cells, whether it's umbilical cord or embryonic stem cells or adult stem cells, it brings the topic back up to the lay public that these are very important cells," ViaCell Inc. (VIAC :
viacell inc com Last: 5.65+0.15+2.73%
12:14pm 03/22/2007 VIAC5.65, +0.15, +2.7% ) Chief Executive Marc Beer said. Click here for broadband interview.
But more education is needed. Although one camp of investors is sophisticated enough to understand the world of stem cells and the differences among them, another and perhaps larger camp remains flummoxed by -- and subsequently wary of -- this nascent field, and keeps its distance.
"I've talked to investors who say I'm too busy to drill down into the nuances of what you guys are saying," said Aastrom Biosciences Inc. (ASTM : Aastrom Biosciences Inc
Last: 1.34+0.02+1.52% 12:15pm 03/22/2007 ASTM) Chief Executive George Dunbar said.
What investors are really looking for, he said, is proof.
"Investors are saying, enough already -- we want to see clinical data, and until then all you guys are doing is blowing smoke," Dunbar said.
In the meantime, stem cell companies are still looking for funding. The IPO market for the healthcare sector was challenged last year and remains so, said Steve Burrill, who runs the life sciences-focused merchant bank and venture capital firm Burrill & Co. Many companies are instead looking at foreign markets.
"More companies are thinking about very creative ways to finance on a more global scale," he said. "There's a number of capital markets that are attractive and that value companies differently."

[toller]

Stem cell stocks volatile after Senate vote
Many stem-cell-related biotechs shares get hit by Senate vote, but Osiris surges 7 percent.
By Aaron Smith, CNNMoney.com staff writer
April 12 2007: 4:12 PM EDT

NEW YORK (CNNMoney.com) -- Some of the biotechs specializing in stem cell research took a hit Thursday after the Senate voted to remove a ban on federal funding for embryonic stem cell research but not by a wide enough margin to overcome an expected presidential veto.

The declines came even though only two of the companies, Geron and Advanced Cell Technologies, use embryonic stem cells. Geron's (down $0.16 to $7.40, Charts) stock dropped more than 2 percent. Advanced Cell, which is traded over the counter, also fell more than 2 percent.
The other biotechs use stem cells from adult tissue.

StemCells, Inc., (down $0.09 to $2.77, Charts) which according to analysts experiences big swings on these issues thanks to its distinctive ticker symbol - STEM - tumbled nearly 5 percent.

Aastrom Biosciences (down $0.05 to $1.45, Charts), which also uses adult tissue, lost more than 3 percent.

"It's a mystery to us why we track with the pack, because we're not embryonic," said Aastrom Chief Executive George Dunbar to CNNMoney.com.

But Osiris Therapeutics (up $1.54 to $17.60, Charts), which extracts stem cells from bone marrow as opposed to embryos, was an exception, experiencing a surge of nearly 6 percent.

Cytori Therapeutics (up $0.07 to $6.00, Charts), which derives its stem cells from fat tissue, rose nearly 2 percent.

Jose Haresco, analyst for the investment research firm Merriman Curhan Ford, said day traders were buying and selling "off the political momentum" of the Senate vote, even though "it's not related to the companies and the fundamentals of the science at all."

But Stephen Brozak, analyst for the investment research firm WBB Securities, said Osiris and Cytori stocks are up because these companies are the most advanced in getting new stem cell products on the market.

"These are the two companies that are the closest commercially to any kind of revenue going forward in the stem cell space," said Brozak.

Cytori and Osiris both hope to launch new stem cell products in the U.S. market by 2008. Cytori is planning to introduce its Celution System in Europe this year, using stem cells from liposuction fat to rebuild breast tissue in cancer survivors who have undergone partial mastectomies.

Osiris is developing Prochymal, a potential treatment for acute graft versus host disease, an immune condition affecting cancer survivors with bone marrow transplants, and Crohn's disease, which causes inflammation of the digestive tract.

Osiris, based in Columbia, Maryland, is currently the only company with an FDA-approved stem cell-based product on the market. The company produces OsteoCell, which stimulates bone growth.

The Senate voted 63-34 on Wednesday to remove President Bush's 2001 restrictions on federal funding for research involving embryonic stem cells. But the vote failed to reach the two-thirds majority needed to override Bush's expected veto.
Robots grab chunk of prostate surgery biz

In a statement issued after Wednesday's 63-34 vote, Bush said he would veto the new bill, saying it "crosses a moral line that I and many others find troubling."

Stem cells serve as a repair system for the body. They can morph into other types of cells, according to the National Institutes of Health, and scientists hope to harness the cells to repair damage from crippling injuries and diseases.

[toller]

YES! Das ist ein klasse Meilenstein!

FDA Approves Aastrom Phase III IND for Treatment of Osteonecrosis of the Femoral Head
Monday May 7, 5:58 pm ET
Patient-Specific Stem Cell Trial to Address Unmet Medical Need

ANN ARBOR, Mich., May 7, 2007 (PRIME NEWSWIRE) -- Aastrom Biosciences, Inc. (NasdaqCM:ASTM - News), a regenerative medicine company, today announced that the U.S. Food & Drug Administration (FDA) approved the Company's Investigational New Drug (IND) application to initiate a 120 patient Phase III clinical trial for the treatment of osteonecrosis (also known as avascular necrosis) of the femoral head. Aastrom intends this to be a pivotal trial with the goal of demonstrating clinical safety and efficacy for the submission of a Biologics License Application (BLA). In addition, the Company may have to generate further patient data in this indication, such as data from the ongoing pivotal trial in Spain, to support a U.S. BLA submission. Osteonecrosis is a progressive disease, with no established effective treatments, that often leads to a total hip replacement. Aastrom will use its Bone Repair Cell (BRC) product, based on Tissue Repair Cell (TRC) Technology, to evaluate this approach for treating patients suffering from osteonecrosis.

ADVERTISEMENT
``This is our first Phase III clinical trial focused on tissue regeneration, and it represents a significant step forward for both the Company and the field of regenerative medicine. We are thrilled to report the achievement of this clinical milestone,'' said George Dunbar, President and Chief Executive Officer of Aastrom. ``Should the clinical trial results meet our expectations, we intend to seek licensure and take the BRC product to market under our existing Orphan Drug Designation.''

Initiation of this clinical trial complements the receipt of an Orphan Drug Designation from the FDA. Orphan drug status is granted to development-stage products that offer potential therapeutic value in the treatment of rare diseases and conditions. The Company may be entitled to several benefits prior to approval, including an expedited FDA review, the reduction or even elimination of filing fees, and the availability of possible tax credits, and will be entitled to seven years of marketing exclusivity once the product receives FDA approval.

This trial will seek to enroll 120 patients, randomized into two patient groups, at up to 20 clinical sites. The planned treatment approach for all patients will include a core decompression surgery where a core track (hole) is drilled into the head of the femur to relieve internal pressure. Patients randomized into the treatment group will have BRCs mixed with a bone matrix carrier placed into the core track, while control patients will receive bone matrix carrier without cells. If healthy bone can be successfully regenerated in the femoral head, we expect the need for a hip replacement could be delayed or eliminated in osteonecrosis patients. The primary efficacy endpoint of this trial is to prevent or delay the progression of osteonecrosis to fracture, and potentially collapse of the femur head, which will be measured by a blinded third-party reviewer through MRI and CT imaging. Patients will be followed for a total of 24 months, post-treatment.

``Osteonecrosis is a pressing medical problem in orthopedic medicine. This disease generally afflicts younger people, and often has a poor prognosis. More than half of the patients progress to debilitating fractures of the femoral head which require a total hip replacement without appropriate treatment, within two years of initial diagnosis,'' said Marc W. Hungerford, M.D., Assistant Professor of Orthopedics at the Johns Hopkins University School of Medicine. ``This trial represents a novel and promising approach aimed at preserving the functional integrity of the hip joint. It could potentially eliminate the need to subject the patient to major surgery.''

The tissues involved in osteonecrosis of the femoral head include bone, bone marrow and blood vessels (vascular), complicating the development of effective treatments in the past. Aastrom's TRC-based products, which include a proprietary mixture of stem and progenitor cells derived from a small sample of the patient's own bone marrow, have been used in other clinical trials involving different indications to evaluate regeneration in all three of these tissues. With this capability, the application of TRC Technology may offer a novel means to regenerate the tissues lost due to osteonecrosis.

This study initiation is Aastrom's second clinical trial evaluating the Company's TRC Technology in patients with osteonecrosis of the femoral head. In January, the Company announced it had treated the first two patients in a pivotal clinical trial for osteonecrosis in Spain.

About Osteonecrosis

The National Osteonecrosis Foundation indicates that in the U.S. alone, there are up to 20,000 people initially diagnosed with this debilitating disease each year, and current therapies are of limited effectiveness. Osteonecrosis is a painful medical condition where the tissue inside a bone is dying and unable to regenerate itself through natural processes. Ninety percent of the patients afflicted by this disease have osteonecrosis at the femoral head -- the ball at the top of the femur bone that rotates inside the hip socket. Left untreated the femoral head eventually collapses, leading to a total hip joint replacement. In the U.S., it is estimated that up to 10% of all hip replacements are performed due to osteonecrosis. There are no established pharmaceuticals for the prevention or treatment of osteonecrosis. For more information, visit the National Osteonecrosis Foundation's website at http://www.nonf.org.

[toller]

dazu noch die Zahlen, die aber nichts wesentlich neues beinhalten. Verlust bleibt annähernd in der Höhe des Vorjahreszeitraumes, die sales sind eh nicht signifikant. Ich würde hier allerdings in Zukunft mit etwas höherem Funding rechnen, zu wünschen wäre es jedenfalls, zumal Aastrom sich nicht auf dem Feld der embryonalen Stammzellen-forschung tummelt (wie z.b. Geron) sondern adulte stammzellen. Daher ist Aastrom auch nicht so von der anhaltenden Debatte im Senat betroffen, wird aber ähnlich wie Stemcells jedesmal mit in den strudel gerissen.

Aastrom bleibt eines der interessantesten Unternehmen, da weiter als viele andere Player in dem MArkt. Bis der Durchbruch gelingt, können allerdings noch einige Winter vergehen...Zumindest rechnet man noch dieses Jahr mit weiteren Milestone Achievements rechnet:

We look forward to reporting the achievement of additional clinical milestones during the remainder of 2007.''


Aastrom Reports Third Quarter Fiscal Year 2007 Financial Results
Tuesday May 8, 7:00 am ET
Company Achieves Multiple Clinical Milestones; Initiates Several Clinical Trials

ANN ARBOR, Mich., May 8, 2007 (PRIME NEWSWIRE) -- Aastrom Biosciences, Inc. (NasdaqCM:ASTM - News), a regenerative medicine company, today reported financial results for the third fiscal quarter ended March 31, 2007. The Company also reported clinical milestones achieved since January of 2007:

* FDA approval of U.S. Phase III multi-center clinical trial to treat
patients debilitated by osteonecrosis of the femoral head. This
prospective, controlled, randomized trial seeks to enroll 120
patients at up to 20 clinical sites.

* Initiation of U.S. Phase IIb multi-center clinical trial to treat
patients suffering from critical limb ischemia, the end stage of
peripheral arterial disease. This prospective, controlled,
randomized, double-blind trial seeks to enroll 120 patients at up to
20 clinical sites.

* Initiation of and patient treatments in a pivotal clinical trial for
osteonecrosis of the femoral head in Spain.

* Receipt of Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) for the treatment of dilated cardiomyopathy
(DCM).

* Positive interim data reported from the U.S. long bone non-union
fracture trial at annual meeting of American Academy of Orthopaedic
Surgeons. To date, multiple bone bridges, which are evidence of
healing, have been observed in 90% of the patients who have
completed the 12 month follow-up.

ADVERTISEMENT

``Last fall we outlined several significant clinical milestones that we wanted to achieve over the course of calendar year 2007. We are pleased with the progress we have made to date, especially with the recent announcements that the FDA approved two of our U.S. clinical trials. Within the last week, we have initiated both a Phase III clinical trial for the treatment of osteonecrosis of the femoral head and a Phase IIb clinical trial to treat critical limb ischemia, both of which are significant achievements. We are recruiting clinical sites for the osteonecrosis multi-center trial. Patient recruitment is currently ongoing for the critical limb ischemia trial, and additional sites are expected to be added over the next few months,'' said George Dunbar, President and Chief Executive Officer of Aastrom. ``We are focused on our goal of bringing TRC-based therapies to physicians and their patients. As we continue to initiate and execute clinical trials in our targeted therapeutic areas, we are building a strong foundation for our future in regenerative medicine. We look forward to reporting the achievement of additional clinical milestones during the remainder of 2007.''

Third Fiscal Quarter Ended March 31, 2007 Results

Total revenues for the quarter and nine months ended March 31, 2007, consisting of product sales and grant funding, were $258,000 and $520,000, respectively, compared to $238,000 and $535,000 for the same periods in fiscal year 2006.

Total costs and expenses for the quarter and nine months ended March 31, 2007 increased to $5,180,000 and $14,766,000, respectively, from $5,037,000 and $13,467,000 for the same periods in fiscal year 2006.

Research and development expenses for the quarter and nine months ended March 31, 2007 increased to $3,096,000 and $7,963,000, respectively, from $2,597,000 and $6,745,000 for the same periods in fiscal year 2006. These increases reflect continued expansion of our research and development activities to support future regulatory submissions, on-going and planned tissue regeneration clinical trials in the U.S. and EU and the development of facilities for product manufacturing. Research and development expenses for the quarter and nine months ended March 31, 2007, also include non-cash charges of $202,000 and $492,000, respectively, compared to $90,000 and $288,000 for the same periods in fiscal year 2006, relating to share-based compensation expense.

Selling, general and administrative costs decreased for the quarter, and slightly increased for the nine months, ended March 31, 2007 to $2,070,000 and $6,786,000, respectively, from $2,438,000 and $6,711,000 for the same periods in fiscal year 2006. For the quarter and nine months ended March 31, 2007, these costs include non-cash charges of $501,000 and $1,656,000, respectively, compared to $200,000 and $503,000 for the same periods in fiscal year 2006, relating to share-based compensation expense.

Interest income for the quarter and nine months ended March 31, 2007 increased to $439,000 and $1,481,000, respectively, from $250,000 and $753,000 for the same periods in fiscal year 2006. The fluctuations in interest income are due primarily to corresponding changes in the level of cash, cash equivalents and short-term investments during the periods, and to improved yields from our investments.

Net loss for the quarter ended March 31, 2007 was $4,483,000, or $.04 per share, compared to a net loss of $4,549,000, or $.04 per share for the same period in fiscal year 2006. Net loss for the nine months ended March 31, 2007, was $12,765,000, or $.11 per share, compared to $12,179,000, or $.12 per share for the same period in fiscal year 2006. The change in net loss per share for the nine month periods is primarily the result of increased costs and expenses offset on a per share basis by an increase in the weighted average number of common shares outstanding.

At March 31, 2007, the Company had $32.6 million in cash, cash equivalents and short-term investments as compared to $43.0 million at June 30, 2006.

[toller]

bischen eingeschlafen die gute Branche...vielleicht sorgt dass für Stimmung bei Aastrom, nachbörslich in USA zumindest ein bischen gestiegen.

http://biz.yahoo.com/pz/070627/122095.html

First Patient Treated in Aastrom Adult Stem Cell Trial for Critical Limb Ischemia
Wednesday June 27, 5:47 pm ET
Five Sites Initiated for Phase IIb Trial in U.S.

ANN ARBOR, Mich., June 27, 2007 (PRIME NEWSWIRE) -- Aastrom Biosciences, Inc. (NasdaqCM:ASTM - News), a regenerative medicine company, today announced that the first critical limb ischemia (CLI) patient was treated at the Malcom Randall Veterans Affairs (VA) Medical Center in Gainesville, FL. The Company is evaluating its Vascular Repair Cell (VRC) product in a U.S. Phase IIb clinical trial to treat patients suffering from CLI, the most severe form of peripheral arterial disease (PAD).

ADVERTISEMENT
Approximately 900,000 people suffer from CLI, which leads to 100,000 major amputations per year in the U.S. CLI patients endure chronic ischemia-induced pain (even at rest), ulcers, tissue loss or gangrene in the limbs, and represent the end stage for PAD patients.

``Current surgical or endovascular techniques for limb revascularizations are often limited by anatomic constraints in patients with CLI. These patients suffer from rest pain and frequently have no other options for revascularization. Typically we see these patients over the course of several years. They come to us with severe pain, and on evaluation typically have long segments of their arteries blocked so that it is impossible for us to reestablish blood flow by any conventional means. Unfortunately, these patients often go on to develop gangrene of the toes, requiring successive amputation surgery. Due to inadequate perfusion, the wounds from these surgeries often do not heal, leading to a vicious cycle of repeat amputations with wound healing complications,'' commented Scott A. Berceli, M.D., Ph.D., Principal Investigator at the VA Medical Center. ``The ability to improve blood flow to the limbs in patients such as this through vascular tissue regeneration provides the next generation of therapeutic options, and VRCs stand at the forefront of these approaches.''

Aastrom's VRCs are based on the Company's Tissue Repair Cell Technology, which enables patient-specific stem cell products for multiple regenerative medicine applications. Aastrom manufactures VRCs for vascular tissue regeneration in an automated, GMP (Good Manufacturing Practices) process. Unique in the stem cell industry is the Company's manufacturing technology that enables the production of a consistent and reliable cell product containing large numbers of early stage stem and progenitor cells essential for tissue regeneration.

``Our VRCs are composed of stem and progenitor cells that we believe are required for tissue regeneration in the human body. A normal dose of VRCs contains significantly more of these key cells than can normally be harvested from a patient,'' stated Elmar R. Burchardt, M.D., Ph.D., Vice President, Medical Affairs of Aastrom. ``These large numbers of stem and progenitor cells may be extremely important when treating critical limb ischemia patients with severely impaired blood flow that can affect the majority of their lower leg.''

In addition to the VA Medical Center in Gainesville, FL, four other sites have been initiated and trained, including: Southern Illinois University School of Medicine, Springfield, IL; St. Joseph Mercy Hospital, Ann Arbor, MI; Michigan Vascular Research Center, Flint, MI; and, Vanderbilt University Medical Center, Nashville, TN. Aastrom will update its website as other clinical sites are initiated and trained.

Aastrom's prospective, controlled, randomized, double-blinded, multi-center trial is expected to enroll 120 patients at up to 20 sites, randomized into two patient groups, to evaluate the safety and efficacy of the TRC-based product in the treatment of CLI. Patients from both groups will be followed for a period of 12 months, post-treatment. The primary objective of the clinical trial is to assess the safety of the TRC-based product in CLI patients. Secondary objectives include assessing amputation rates, wound closure and blood flow in the affected limbs, patient quality of life, and the reduction of pain and analgesic use. Once the first 30 patients have completed the 12-month follow-up, Aastrom will analyze the interim results from these patients. Data gathered from this clinical trial will provide the scientific and statistical basis for an anticipated pivotal trial in the vascular regeneration area.

[toller]

After Hours Trade Reporting

After Hours Last: $ 1.40
After Hours High: $ 1.42
After Hours Volume: 39,853
After Hours Low: $ 1.3179

[toller]

aktuell (seit ca. 2 Wochen leicht steigende kurse mit zunahme in den letzten drei Handelstagen) können einige Stammzellenaktien wieder gut zulegen, darunter insb. Aastrom und Stemcells.
Wohl auch weil:
- PerkinElmer VialCell mit rd. 50% aufschlag übernommen hat (und wohl demnächst die R&D von Vialcell ausphasen und weiterverkaufen wird)
- Biotechs in letzter Zeit stark attraktiver geworden sind aufgrund voller Pipelines
- einige wichtige große investorenkonferenzen anstehen.

speziell bei AAstrom rechnet man im Oktober mit der Bekanntgabe einiger wichtiger Ergebnisse (u.a. hab ich irgendwo gelesen, dass ein Prof. in Würzburg auf dem Europ. Stammzellenkongress irgendeine Studie von Aastrom vorstellt) bzw. dem Start von weiteren Programmen.

Upcoming Milestones (aus einer Investment Analyse)

1) On October 4th, data will be presented for Aastrom TRCs in early EU compassionate use osteonecrosis and interim data for EU critical limb ischemia. On October 18th, final data from
the U.S. Phase I/II for long bone fractures will be presented at the Orthopedic Trauma Association meeting in
Boston.
2) Enrollment beginnt für U.S. Critical Limb Ischemia (CLI) Phase IIb.
3) IND Approved for Aastrom’s First U.S. Pivotal Phase III Clinical Trial: In May, Aastrom announced they
received the FDA IND to initiate their Phase III trial for osteonecrosis of the femoral head. The trial will enroll
120 patients, randomized into two patient groups, at up to 20 clinical sites. We expect the first patient to be
enrolled in Q4.
4) Weitere clinical trials werden für 2008 im Bereich Dilated Cardiomyopathy in der EU und US erwartet, und Treials im BEreich Spinal Cord Injury.


Insgesamt denke ich es wird wieder spannend. In den letzten Wochen gab es wieder genügend Gelegenheiten, auch durch den Dollar/Euro Kurs recht günstig Aastrom Aktien aufzustocken. Wenn der Dollar allerdings weiterhin schwächelt (nja, ehrlich gesagt rechne ich fast damit) ist ein Investment in EUR natürlich immer um den jeweiligen Kursverfall schlechter...Anyway, ich denke das Jahresende wird für die gesamte biotech-Branche spannend.

[toller]

STEM 4:01PM ET 2.46 Up 0.29 Up 13.36%
ASTM 4:01PM ET 1.37 Up 0.15 Up 12.30%

[toller]

wie angekündigt, pünktlich zum 4.10.:

Aastrom Announces Positive Interim Results From Phase I/II Study Involving Use of Vascular Repair Cells in Patients With Critical Limb Ischemia
Thursday October 4, 8:00 am ET


Results Presented Today At the Congress of the German Society for
Stem Cell Research in Wurzburg, Germany

Early Clinical Data Supporting Use of Aastrom Bone Repair Cells
(Brcs) in Treatment of Osteonecrosis of the Femoral Head Also
Presented

ANN ARBOR, Mich., Oct. 4, 2007 (PRIME NEWSWIRE) -- Aastrom Biosciences, Inc. (NasdaqCM:ASTM - News), a leading regenerative medicine company, today announced positive interim results from two separate research groups utilizing autologous stem cell products manufactured with the Company's proprietary Tissue Repair Cell (TRC) Technology platform. The first study reported positive results from the use of Aastrom Vascular Repair Cells (VRCs) in the treatment of chronic diabetic foot wounds associated with critical limb ischemia (CLI). In another presentation, positive results from the use of Aastrom Bone Repair Cells (BRCs) in the treatment of osteonecrosis of the femoral head were presented. Primary investigators from each of these research groups presented data today at the 2nd Congress of the German Society for Stem Cell Research in Wurzburg, Germany.

ADVERTISEMENT
In an oral presentation, Dr. Bernd Stratmann of the Diabetes Center at the Heart and Diabetes Center in North Rhine-Westphalia (Center), Bad Oeynhausen, Germany, presented interim results from the first 13 patients treated in a multi-arm Phase I/II single-center clinical trial to evaluate the safety of VRCs and normal bone marrow cells in the treatment of chronic diabetic foot wounds associated with CLI. Results reflect treatment experience from: four diabetic patients with ischemia-related chronic tissue ulcers who were treated with Aastrom VRCs, a cell mixture derived from the patient's bone marrow that is processed using TRC Technology to generate large numbers of predominantly mesenchymal stem and early progenitor cells; seven patients who were treated with normal bone marrow cells; and two standard of care patients who received no cells. All patients received standard wound care as described by the American Diabetes Association.

Twelve months post-treatment, all patients in the interim analysis who were treated with VRCs reported no major amputations, no cell-related adverse events, and healing of all open wounds. Of the seven patients treated with normal bone marrow cells, five reported results similar to the VRC-treated patients 12 months post-treatment, one reported similar results to the VRC-treated patients 18 months post-treatment, and one patient received a major amputation. For the two standard of care patients who only received wound care (no cells), one patient received a major amputation and one patient experienced no improvement in wound healing after 12 months.

``These encouraging results indicate that VRCs are safe for therapeutic use and could offer potential advantages over the current standard of medical care in closing chronic wounds and in reducing the risk of amputation for diabetic patients with CLI,'' said Dr. Stratmann, who is a primary investigator in the trial along with Stanley Kirana, M.D., and Prof. Diethelm Tschope, M.D., medical director of the Center.

In a second oral presentation at the same meeting, clinical results were presented by Ulrich Noth, M.D. of the Orthopaedic Institute, Konig-Ludwig-Haus, University of Wurzburg, Germany, involving the first use of Aastrom BRCs to treat patients suffering from osteonecrosis of the femoral head. Osteonecrosis of the femoral head involves the death of cells in the bone and marrow within the femur head and in many cases leads to total hip replacement. Dr. Noth presented data from 4 patients. All patients tolerated the procedure well, have reported a reduction in hip pain with no signs of disease progression, as determined by MRI and X-Ray, and were back to work within 6 months after treatment. In addition, no cell-related adverse events were observed and none of these patients have required hip replacement surgery.

``There are currently no effective treatment options for terminating or reversing this disease process. The use of cell-based therapies has great potential and could play an important role in the treatment of femoral head necrosis in the future,'' said Dr. Noth.

``In both of these studies, we see more encouraging safety and efficacy data suggesting clinical benefits from treatment involving products derived from Aastrom's Tissue Repair Cell Technology platform. These data demonstrate, for the first time, that Aastrom's cell products may have a beneficial long-term effect in these two key indications: critical limb ischemia and osteonecrosis of the femoral head. Although still early, the results presented here lend substantial scientific support to our entire clinical development program that is focused on autologous stem cell products for regenerative medicine,'' said Elmar R. Burchardt, M.D., PhD., Vice President, Medical Affairs of Aastrom.

[diegutefee]

Hallo toller,

vielen Dank für Dein Engagement!

Aastrom ist ein "blauer Diamant"!

Leider wird der Kurs dieser Aktie ständig gedrückt!

Wäre "Aastrom" eine "chinesische Firma", würde eine
Aktie mindestens 50 $ kosten!

Herzliche Grüße

diegutefee



P.S.:
Die "Edelsteine" muß man erkennen und einsammeln!

[Gulliver]

naja,

die Stammzellenforschung stellt schon einen aussichtsreichen Geschäftssektor dar - leider seit ihr an der falschen Firma hängen geblieben...

cu gulliver

[toller]

Antwort auf Beitrag Nr.: 31.934.703 von Gulliver am 11.10.07 09:11:54

echt, und welche sollte deiner meinung nach die richtige sein?

[diegutefee]

Hallo Gulliver,

Viacell und Lifecell habe ich bereits verkauft!

Herzliche Grüße

diegutefee



P.S.:
Ich kaufe überwiegend unterbewertete "Perlen"!

[Gulliver]

guckst du hier

Thread: Cytori Therapeutics (ehem.MacroPore)-einfach riesiges Potential!

[toller]

grund für den starken Rückgang der letzten Tage s.u. - wie zu erwarten war geht es jetzt wieder aufwärts, so ein Placement ist natürlich immer ne Verwässerung, allerdings zeigt die Erfahrung, dass gerade bei Bios (oder auch Explorern und anderen solchen emerging companies) der kurs nach einem erfolgreichen Placement recht schnell wieder nach oben geht, da die weitere Forschung/Trials gesichert werden. Also hoffen wir mal, dass bald ein announcement kommt, dass das Placement erfolgreich abgeschlosen wurde.

bei finance.yahoo.com (symbol=astm) gibts noch ne weitere news, dass am montag ein update kommt zu U.S. Phase I/II Severe Fracture Trial:
http://biz.yahoo.com/bw/071016/20071016006234.html?.v=1

hier die meldung zum placement:

Aastrom Direct Offering to Raise $13.5M
Tuesday October 16, 10:12 am ET
Aastrom Biosciences Plans Registered Direct Offering of 11.8 Million Units at $1.14 Per Unit

ANN ARBOR, Mich. (AP) -- Aastrom Biosciences Inc., which develops technology to repair tissue cells, said Tuesday it plans to raise about $13.5 million in a registered direct offering of 11.8 million units to a group of institutional investors.


The price of the offering is $1.14 per unit. Each unit consists of one share of the company's common stock and a warrant to buy 0.5 shares of Aastrom stock at $1.59 per share, a 25 percent premium to the stock's closing price on Oct. 15.

The warrants are exercisable after six months and one day from the date of issuance for a period of five years. If the warrants are exercised, Aastrom will receive an additional $9.4 million in proceeds.

The offering is expected to close within the next few days, the company said. BMO Capital Markets is the lead manager of the offering.

Aastrom shares dropped 17 cents, or 13.4 percent, to $1.10 in morning trading. Shares have traded between $1.08 and $1.67 in the past 12 months

[diegutefee]

Hallo Freunde,

meine Meinung: "Heute ist Kaufsignal!"

Herzliche Grüße und schönen Abend!

diegutefee

[Schapekop]

Antwort auf Beitrag Nr.: 32.138.653 von diegutefee am 24.10.07 19:49:48

Das mit dem Kaufsignal war wohl nicht so ganz richtig:



und am Montag steht ein weiteres Blutbad an in Sachen ASTM - ein Notice of Delisting or Failure to Satisfy a Continued Listing Rule ist im Hause Aastrom reingeflattert. Alles halb so wild man hat noch 6+ Monate um wieder über 1$ so kommen und es gibt natürlich auch Reverse Splits.

Jedoch der oberflächliche Anleger wird erst mal in Panik der Verkaufsknopf drücken und seinen Tax loss nehmen. Ohne Zweifel

Was bedeutet das?

Closing price am Freitag 21-12 war 59 c- sage mal es geht auf 50 c runter (kann auch deutlich mehr sein) haben wir ein Market cap von 66 Mio$- Enterprise value, also Market Cap minus cash im falle von ASTM (so 34 Mio am Ende des jahres) ist dan grob 30-32 Mio$.

Was man dafür kriegt steht eigentlich wunderbar beschrieben in diese Mail von ASTM IR - ist sehr lesenswert.

Disclosure- ich habs nicht so mit ASTM, bin sehr schwer investiert in CYTX ( Thread: Cytori Therapeutics (ehem.MacroPore)-einfach riesiges Potential!), die ich eine viel bessere Zukunft bescheinige, aber denke schon am Tauschen von 1-2k CYTX in 10-20k ASTM nur aus Diversifikationsgründe und wegen Übertreibung des Marktes, was öfters mal vorkommt.

Hier die IR Mail-

Thank you for your interest in Aastrom Biosciences, Inc.

During the Annual Meeting of Shareholders held on November 7th and during the 1st Q FY2008 conference call held on Friday, November 9th, Mr. Dunbar reiterated his displeasure with the stock price in light of Aastrom's clinical progress over the last 12 months or so. A portion of Mr. Dunbar's comments included:

I would like to take a moment to recap one of the most important topics discussed at the Annual Meeting of Shareholders earlier this week...it is a topic we are hearing about frequently these days...our share price.
I can assure you that we are on course, with wind in our sails to proceed into and through the clinic as rapidly as possible, and ultimately create value for our shareholders. I think the best analogy that I can give right now starts with your home and your health, your most major investments. Let's say you just finished, or are in the middle of a remodeling project on your home. And the company you work for announces that they are closing the local facility, and several thousand people are going to be let go or redeployed. You then read in the paper about the credit decline, the mortgage crisis, and the failing capital market, and all of a sudden houses in your neighborhood and area are going down in price. Now, if you are intending to sell then that's a problem. But if you are intending to stay and hold and invest, there may even be a buying opportunity for some to take advantage of. Let's take a moment to recognize that in many ways this analogy is similar to where Aastrom is today.

The capital markets are in very difficult shape. We recently concluded a financing because it is important to fund our current clinical trial programs and provides financial flexibility if the current market conditions continue. We have some very exciting clinical trials ahead of us and we are putting the maximum resources into these programs.
We've got some very exciting opportunities ahead of us in the cardiac and neural areas, where we will be talking to you in the near future about the patients whom we expect to treat. These clinical programs require money and capital to fund operations. So we will be raising money from time to time.

There are short-term peaks and valleys in our stock, and a lot of trading activity around both Aastrom and industry news flow. Our stock is volatile, and lately the trend has been down. This is a trend that the entire sector has been experiencing. All of our stock prices react to most news or market fluctuations in the same way.

Aastrom is fundamentally strong and our goal is to break out of this "pack", and we have laid a foundation for building value that will make a difference. We are breaking ground on numerous fronts:
- We're creating a new class of therapeutic products
- We're blazing new pathways with regulatory agencies, such as the FDA, and
- We're forging collaborations and relationships with research institutes, physicians and insurers

This is a complex process...it takes years...it takes significant investment...and we think it is worth it, because we HOPE that our therapies will change the lives of patients suffering from severe injuries and diseases who have limited medical options today.

Over the last year we have achieved a number of important clinical milestones in the development of our Tissue Repair Cell-based products for regenerative medicine, including the following:

Vascular Regeneration
Initiated RESTORE-CLI trial - U.S. Phase IIb critical limb ischemia trial (April 2007) Reported positive interim data from CLI patients treated in EU clinical trial (October 2007)

Bone Regeneration
Initiated ON-CORE trial - U.S. Phase III osteonecrosis trial (May 2007) Initiated patient enrollment in ON-CORE trial (June 2007) Initiated pivotal osteonecrosis trial in Spain (January 2007) Obtained Orphan Drug Designation from FDA for osteonecrosis of the femoral head (March 2006) Reported positive early EU compassionate use osteonecrosis patient data (October 2007) Reported final U.S. Phase I/II long bone fracture trial results (October 2007)

Cardiac Regeneration
Obtained Orphan Drug Designation from FDA for dilated cardiomyopathy (February 2007)

With these clinical activities underway, we are on track with several clinical milestones targeted for the coming months, including:

Cardiac Regeneration
Initiate EU cardiac clinical activity (2007) Analyze EU cardiac interim data - 6 months after patient treatments (2008) Submit U.S. IND for Phase I/II clinical trial (2008) Submit EU IMPD for Phase I/II clinical trial (2008)

Neural Regeneration
Initiate EU spinal cord injury clinical activity (2008)

We also hope that you have seen the latest Form 4s filed for several officers and directors. Mr. Dunbar, our CEO, and Mr. Brennan, our CFO, have each purchased 20,000 shares on the open market, and one of Aastrom's directors, Nelson Sims, purchased 10,000 shares.

Aastrom has always followed a strict protocol concerning 'news', in that when a material event occurs, we issue a press release for full public disclosure to our investors and the investment community at large; these press releases are often distributed concurrent with 8-K filings with the SEC.

xxxxxx, thank you for your continued interest in and support of Aastrom!


Happy bargain hunting